Day: September 29, 2025

EXOSENS SECURES MAJOR CONTRACT WITH THE SPANISH ARMY FOR 17 000 ADVANCED NIGHT VISION MONOCULARS PRESS RELEASEMÉRIGNAC, FRANCE – SEPTEMBER, 29th 2025Exosens announces that the Spanish Ministry of Defense, has signed a supply contract of 17 000 night vision monoculars to its recent acquisition NVLS, using Exosens’ 16 mm 4G intensifier tubes, to be delivered from 2025 to 2028. NVLS contributes to European sovereignty by reinforcing its industrial capacity as a key Spanish supplier for night vision equipment for dismounted soldiers. Exosens continue to fully benefit from growing demand in night vision as the strategic supplier to NATO member states and allies of both image intensifier tubes and night vision equipments.Exosens strengthens its position as a key supplier to Spanish Forces for night vision image intensifier based equipment Exosens,...

Sampo plc, stock exchange release, 29 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 26 September 2025                                                  On 26 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,154 9.59 AQEU    137,794 9.61 CEUX  40,402 9.60 TQEX  188,907 9.61 XHELTOTAL 371,257 9.61  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

OSLO, Norway (29 September 2025) – TGS, a global leader in energy data and intelligence, announces the commencement of a new multi-client Ultra-Long Offset Ocean Bottom Node (OBN) data acquisition campaign in the Gulf of America. The Amendment West-1 survey is TGS’ second campaign expanding multi-client node coverage in the Paleogene West play, adding more than 5,400 square kilometers within the East Breaks protraction area. Amendment West-1 will feature TGS’ Gemini™ enhanced frequency source and TGS’ ZXPLRe™ nodes. The Gemini source has been engineered to generate increased low-frequency energy for deep penetration and Full Waveform Inversion (FWI), while preserving high-frequency content necessary for conventional processing and imaging workflows.   The Amendment West-1 dataset, to be processed by TGS’ Imaging experts,...

Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 22 September up to and including 26 September 2025 a total of 57.112 shares were repurchased at an average price of €16.756 for a total amount of €956,979.58 To date, the total consideration for shares repurchased amounts to €3,551,493.30 representing 35.51% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website: https://www.corbion.com/Investor-relations/shareholder-information This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.Attachment2025 SBB weekly update 202509026

Company AnnouncementGenmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDTCOPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3 development, for USD 97.00...

Next generation sustained-release formulations for a variety of peptides Executive summaryfirst biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new formulations liquid formulation allows flexible dosing through adjusting injection volumes perseverance during 10 years of in-house researchMELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) — CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug release profiles. A decade of investment in fundamental research & development in CLINUVEL’s fully-owned Singaporean laboratories (VALLAURIX) has provided positive, consistent results demonstrating the potential...

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX 4 Product Execution Plan Announced, will be the First Potential Model Under the FX Brand Designed for the Volume MarketFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX 4 Product Execution Plan Announced, will be the First Potential Model Under the FX Brand Designed for the Volume MarketFX Super One Middle East Final Launch event will be held on October 28, start of the first deliveries in the Middle East planned for November of this year. FF and FX will join WETEX 2025 in Dubai from September 30 to October 2, one of the largest and most influential exhibitions for sustainable and clean energy in the Middle East.LOS ANGELES, Sept. 28, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday...